at Investor's Business Daily (Thu, 6:49PM)
Biogen's (BIIB) longer-lasting multiple sclerosis drug peginterferon beta-1a meets the goals of a Phase III trial, helping to cut patients' risk of relapse by 36% when injected every two weeks, and by 28% when given every four weeks. Peginterferon is a version of Biogen's blockbuster Avonex medicine, which is taken once a week. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Investor's Business Daily (Thu, 6:38PM)
at Zacks.com (Tue, 12:00PM)
at Nasdaq.com (Mon, 11:41AM)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs